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868-i Percutaneous Left Atrial Appendage Transcatheter 
Occlusion (PLAATO ) to Prevent Stroke in Patients 
With Atriai Fibrillation: initial Results of the Multicenter 
Feasibility Trial 
Horst Sievelt, Michael D. Lesh. Stefan Ostermayer, Kai Billinger, Thomas Trepels, 
Heyder Omran, Antonio L. ??artorelli, Paolo Della Bella, Toshiko Nakai, Mark Reisman, 
William Gray, Carlo DiMario, Peter C. Block, Paul Kramer, David 0. Williams, Athena 
Poppas, Allan Skanes. Ulrike Krumsdorf, Detlef Scherer, Cardiovascular Center 
Bethanien, Frankiurt. Germany, Univ. of California, San Francisco, CA 
Background: Thromboembolism due to atrial fibrillation (AF) is a frequent cause of 
stroke. More than 90 % of thrombi in AF form in the LAA. Catheter closure of the LAA 
might prevent stroke in AF. In this multicenter trial 52 pts with AF (age=70 f 7 yrs; MI 
F&!/20) and additional risk factors for stroke who were sub-optimal candidates for war- 
farin were enrolled. 
Methods: The PLAATO system consists of a self-expanding cage covered with ePTFE 
delivered through a 12Fr transseptal sheath specially designed to access the LAA. It is 
retrievable before release and can be replaced with an alternate size to optimize sealing. 
Results: Device implanta8on (diameters 18.32mm) was successful in all pts, in one dur- 
ing a second procedure. Angiography and transesophageal echocardiography during the 
procedure showed that the device was well-seated in all patients. Hemopericardium 
occurred in 3 (pericardiocentesis performed without sequelae) but all had successful 
implantation, esophageal bleeding due lo TEE in 1. No migration, mobile thrombus or 
interference with cardiac structures was noted on TEE performed 1 and 8 mos post pro- 
cedure. In 1 pt. a laminar echogenic layer representing possible thrombus was noted on 
the implant surface at 1 and 8 mos. No clinical events have occurred in this pt. During fol- 
low up (median 4.5 mo) one pt died 7 mo post implant. He had a history of diffuse athero- 
sclerotic vascular disease and multiple prior strokes. TEE performed 2 weeks prior to 
death showed the device well positioned with no thrombus. 
Conclusions: Transcatheter closure of the LAA with a novel implanted device is feasi- 
ble, and safe during short term follow up. Longer term studies will be needed to show that 
this technology reduces stroke in pts with AF who are sub-optimal candidates for antico- 
agulation. 
8:45 a.m. 
868-2 Outcomes From Carotid Artery Stenting in Over 1,000 
Cases From a Single Group of Operators 
Gishel New Gary S. Roubin, Sriram S. lyer, George Dangas, Roxana Mehran, Yuliya G. -I 
Adamyan, Thosaphol Limpijankit, Christina Brennan, Palawi Kumar, Jiri J. Vitek, Lenox 
Hill Heart and Vascular Institute, Cardiovascular Research Foundation, New York, NY 
Background: We repori the 8year experience of a single group of operators in over 
1000 carotid stenting (CS) procedures. 
Methods: Patients were enrolled and prospectively followed from September 1994 until 
August 2002. Neuroprotection devices were introduced in January 2000. Patient demo- 
graphics, procedural details, 30-day events and long-term follow up data were collected. 
Results were also annualized to determine if there was an improvement over time in peri- 
procedural results. 
Results: 1068 patients underwent CS of 1202 arteries. The mean age of the patients 
was 71 f 10 years. 34% were female with 15% of patients were >80 years of age. 60% of 
patients had concomitant CAD. 10% had contralateral occlusions and 17% had a history 
of prior carotid endarterectomy. Procedural success was achieved in 99% of cases. 33% 
of patients had their procedure performed using a neuroprotection device. Data annual- 
ized in the table below shows a significant reduction in stroke over the 8-year time-period 
(Chi-Square for Trend Analysis). The only multivariate predictors of stroke were hyper- 
tension (p < 0.05). age > 80 yrs (p < 0.05) and symptomatic status (p < 0.05). 
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Conclusion: Improvements in technique, equipment, pharmacotherapy and the use of 
g 
neuroprotection have contributed to the dramatic decline in event rates in the more 0 
recent years of this study. Stroke rates from carotid stenting have declined to levels com- 5 
parable or better than randomized surgical trials. 
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Transcatheter Closure of Post-infarct Ventricular Septai 
Defects: immediate and Mid-Term Results of U.S. 
Registry Using the Amplatzer Post-Infarct Ventricular 
Septai Defect Occiuder 
Background: Post infarction rupture of the ventricular septum carries a grave prognosis. 
Surgical closure of such defects is associated with very high mortality and morbidity. 
Recent advances in device technology may potentially replace surgical closure in these 
patients. We report the initial and mid-term results of a US registry using the Amplaizer 
post-infarct VSD occluder. 
Methods: Ten patients (7female) with post infarct ventricular septal defects (PIVSD) 
underwent an attempt of closure of their defects at a median age of 73 yr. (range 52-86 
yr.). The median size of VSD as measured by echocardiographylangiography was 13.5 
mm (range 8-18 mm). Six patients had prior unsuccessful surgical intervention for the 
VSD. The procedure was performed under general endotracheal anesthesia in 7. 
Results: All patients tolerated the catheterization procedure. Devices were deployed from 
the right internal jugular vein in 8 patients and from femoral vein in two. The sizes of 
devices deployed ranged from 12-22 mm. In 9 patients the attempt was successful in 
deploying the devices and in one the device could not be secured across the VSD. The 
median fluoroscopy time was 36 minutes (15-63 minutes) and the median total proce- 
dure time was 131 minutes (range 76-229 minutes). Immediately after the procedure, the 
shunt disappeared completely in 1; 3 had trivial shunt and in 4 the shunt was small. Com- 
plications encountered during or after the procedure included hematoma requiring trans- 
fusion in one; pacemaker for pre-existent sinus node dysfunction in one and 
tracheaostomy for ventilator dependence in one. At a follow-up interval of &months, five 
patients are alive and doing well. Conclusion: Catheter closure of PIVSD using the 
Amplatzer device is safe and effective. Further clinical trials are underway. 
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868-4 Nitinoi Stent Fractures in the Superficial Femoral 
Artery: incidence and Clinical Significance 
Krishna J. Rocha-Sinqh, Karen Scheer. Janiece Rutherford, Prairie Heart Institution, 
Springfield, IL 
Background: Nitinol stems combine the advantages of excellent radial strength and 
scaffolding with non-compressibility and minimal foreshortening. Originally designed for 
use in the carotid artery, nitinol stents are increasingly being used to treat suboptimal/ 
failed percutaneous transluminal angioplasty (PTA) results in the superficial femoral 
artery (SFA). However, preliminary six month angiographic follow-up in a small cohort of 
SFA nitinol stent patients has recently revealed the unexcepted and previously unre- 
ported finding of stem strut fractures. The incidence and clinical significance of nitinol 
stent fractures in the SFA is unknown. 
Methods: We retrospectively identified 78 patients (84 limbs, 92 lesions) in which 105 
nitinol stems were implanted between January 1999 and November 2001 after subopti- 
mallfailed PTA for severe claudication (93%) or critical limb ischemia. To date, 14 
patients have returned for fluoroscopic assessment of the nitinol stem skeleton: 10 
patients received 15 SMARTTM stents, five received six DynaLinkTM stems, and one 
received one MemothermTM stent. All 14 patients had SFA color duplex-doppler assess- 
ment at the time of fluoroscopic follow-up to assess stent patency. The mean follow-up 
was 18.4 * 9.8 mos. post-procedure (range Smos. to 43 mos). 
Results: All stem procedures were successful; no patient experienced abrupt or sub- 
acute stent closure. No patient required percutaneous or surgical revascularization of the 
index extremity at follow-up. Three of the 22 stents evaluated (13.6%) had fluoroscopic 
evidence of stent strut fractures resulting in stem deformation; one of the three stems 
met duplex doppler criteria for restenosis.The overall stent restenosis rate in the 14 
